Drug Discovery

#Analysis #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays – New technology for the proteomics era

Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More

#Archive

#ADME / Tox #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High throughput screening #Immunology #Lead discovery #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Toxicology

Unrealised wealth in the avalanche of science

Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Pathology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics

Stem Cells – The long march forward to the clinic

Stem Cells - The long march forward to the clinic By Dr Alan Colman The area of cellular therapeutics has never been readily embraced by 'Big Pharma', with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Business #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #Lead discovery #Lead optimisation #RNA #Target validation

Outsourcing life science informatics solutions

Outsourcing life science informatics solutions By Dr Steve Gardner The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that support rapid and… Read More

#Archive

#Analysis #Biomarkers #Business #Clinical specialities #Drug development #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Molecular medicine #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology

Pharmacogenetics – A review of concepts and contents

By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Pharmacogenomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Regenerative Medicine – Promising answers in the face of an ageing population

By Dr Doros Platika As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. Regenerative… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Patent Law #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Protein Therapeutics – New ladders up the fruit tree

Protein Therapeutics - New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or - in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Business #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Pharmacogenomics #Regulatory #RNA #Screening #Target validation #Toxicology

Biologically Relevant Chemistry

Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Chemical engineering #Chemistry #Drug discovery #Genomics #High throughput screening #Lead discovery #Mass spectrometry / NMR #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology

Implementation or algorithm? The value of Bioinformatics

Implementation or algorithm? The value of Bioinformatics By Dr Christopher Hogue Recently the value of bioinformatics has been questioned. The value can be proven but are there enough qualified and professionally trained people who know how to build good bioinformatics tools? At the BIO convention in New York recently, I… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Protein chemistry / Proteomics #RNA #Screening #Target validation #Therapeutics #Toxicology

Pharmaceutical Industry R&D Partnering Strategies

Pharmaceutical Industry R&D Partnering Strategies By Riccardo Pigliucci Drug Discovery With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact 'formula for success' there are many 'success factors' that can be utilised to reduce the risk… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Pharmacology #Pharmokinetics #Preclinical #RNA #Toxicology

e-R&D – The internet at work

e-R&D - The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Clinical specialities #Clinical trials #Drug development #Drug targets #Pharmacology #Regulatory #RNA #System biology

Modelling and simulation in drug development, promise and reality

Modelling and simulation in drug development, promise and reality By Dr Mark Sale Modelling and simulation in drug development is not new. What is new is the vision for moving from a descriptive role (what happened) to a predictive and therefore decision making role. While seemingly attractive, important hurdles, both… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Increasing the chances of lead discovery

Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

The Genie in the Test Tube – From Gene to Gene Therapy: Part 2

The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA

The promise of pharmacogenetics and pharmacogenomics

The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More

#Archive

#Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #QA/QC #RNA #Screening #Stem cells #Target validation #Toxicology

High Throughput Screening (HTS) – Where next?

High Throughput Screening (HTS) - Where next? By Dr Mark Beggs After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world; the resolution of which… Read More

#Archive